1 The actions of adenosine A2A receptor agonists were examined on GABAergic synaptic
transmission in the globus pallidus (GP) in rat brain slices using whole‐cell patch‐clamp …

In high throughput screening of our file compounds, a novel structure 1 was identified as a
potent A2A receptor antagonist with no selectivity over the A1 adenosine receptor. The …

There is now growing interest in the functional role of adenosine A2A receptors. Their
distribution within the brain is restricted in the basal ganglia, particularly abundant in the …

A target neuron of adenosine A2A receptor antagonists to exert anti-parkinsonian activities
has been currently identified to be, at least in part, striatopallidal medium spiny neurons …

It is pointed out that Ca2+-dependent modification rules for NMDA-dependent (NMDA-
independent) synaptic plasticity in the striatum are similar to those in the neocortex and …

Parkinson's disease is the second most common neuro degenerative disorder and affects
over 1 million people in North America. The pathological process, degeneration of the …

Parkinson's disease (PD) is a progressive neurodegenerative disorder, characterized by the
selective loss of dopaminergic neurons of the nigrostriatal pathway. Epidemiological studies …

Adenosine A 2A receptor antagonists are classified to be a recent new therapeutic strategy
for the symptomatic treatment of Parkinson's disease, a hypokinetic movement disorder …

The expression of the human adenosine A2A receptor was examined by reverse
transcription polymerase chain reaction in post-mortem human brain tissue that was …

Long-term L-dopa treatment of Parkinson's disease can lose its effectiveness and cause
development of motor complications such as dyskinesia. Furthermore, L-dopa therapy does …